Liver Transplantation in Alpha-1 Antitrypsin Deficiency: A Retrospective Case-Control Study in a Brazilian Center
Palabras clave:
Alpha-1 Antitrypsin Deficiency, Liver Transplantation, Cirrhosis, Hepatocellular Carcinoma, Retrospective StudyResumen
Objectives: Alpha-1 antitrypsin deficiency (AATD) is a rare genetic metabolic disease curable with liver transplantation (LT). The aim of this study was to comparatively evaluate patients with LT due to AATD and other causes. Methods: Observational, retrospective, analytical, case-control study evaluating 2,511 LT patients, 19 (0.75%) with AATD, from May 2002 to December 2024. Data were obtained by reviewing the medical records and stored in the REDCap program. Results: The median age of AATD and non-AATD (NAATD) patients was similar (56.3 [Δ7-71] and 52.4 [Δ6-78]; p = 0.92, respectively). Males predominated in both groups. The pre-LT Model for End-Stage Liver Disease (MELD)-Na scores for AATD and NAATD patients were 20 (Δ8-24) and 18 (Δ6-72), respectively. Two patients with AATD had positive serologies compatible with previous hepatitis B infection. Three patients also had a clinical epidemiological diagnosis of concomitant nonalcoholic fatty liver disease. The diagnosis of AATD was made only through explant in nine patients (n = 47.4%). The mean pre-transplant alpha-1 antitrypsin dosage was 33.42 mg/dL (Δ19-59.5). All patients who underwent immunophenotyping had the PiZZ phenotype. The indication for LT was decompensated cirrhosis (DC); three patients (16.4%) had concomitant hepatocellular carcinoma (HCC), one diagnosed only in the explant. The incidence of HCC was 15.9% (AATD) and 31.3% (NAATD) (p = 0.34). None of the patients with AATD had severe lung disease. The survival of patients with AATD submitted to LT at 30 days, 1, and 5 years was 94.7, 88.2, and 64.7%, respectively, similar to the other causes (91.4, 80.1, and 68.1%; p = 0.47). Conclusion: AATD was a rare cause of LT due to DC and HCC, predominantly in adults with piZZ phenotype without relevant pulmonary involvement, and whose diagnosis is frequently made after LT. The epidemiology, indication, prevalence of HCC, and survival were similar to those of other causes of LT.
Descargas
Citas
1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med, 2003;168:818-900. https://doi.org/10.1164/rccm.168.7.818
2. Bernspang E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1 antitrypsin deficiency. Respir Med, 2007; 101: 1971-6. https://doi.org/10.1016/j.rmed.2007.04.003
3. Camelier AA, Souza LC, Fernandes ALG, Araújo D, Pereira MC, Mogami R. Deficiência de alfa-1 antitripsina: diagnóstico e tratamento. J Bras Pneumol. 2008; 34(7): 514-27. https://doi.org/10.1590/S1806-37132008000700012
4. Clark VC. Liver transplantation in alpha-1 antitrypsin deficiency. Clin Liver Dis, 2017; 21(2): 355-65. https://doi.org/10.1016/j.cld.2016.12.008
5. Stoller JK, Snider GL, Brantly ML, Fallat RJ, Stockley RA, Turino GM, et al. American Thoracic Society; European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency [German]. Pneumologie, 2005; 59(1): 36-8. https://doi.org/10.1055/s-2004-830176
6. Putnam CW, Porter KA, Peters RL, Ashcavai M, Redeker AG, Starzl TE. Liver replacement for alpha1 antitrypsin deficiency. Surgery, 1977; 81(3): 258-61. Disponível em: https://pubmed.ncbi.nlm.nih.gov/320694/
7. Esquivel CO, Vicente E, Van Thiel D, Gordon R, Marsh W, Makowka L, et al. Orthotopic liver transplantation for alpha-1- antitrypsin deficiency: an experience in 29 children and ten adults. Transplant Proc, 1987; 19(5): 3798-802. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC2903897/
8. Chu AS, Chopra KB, Perlmutter DH. Is severe progressive liver disease caused by alpha-1-antitrypsin deficiency more common in children or adults? Liver Transplantation, 2016; 22: 886-94. https://doi.org/10.1002/lt.24434
9. Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplantation Proceedings, 2008; 40: 1492-4. https://doi.org/10.1016/j.transproceed.2008.02.075
10. Vennarecci G, Gunson BK, Ismail T, Hubscher SG, Kelly DA, McMaster P, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Transplantation. 1996; 61: 1488-95. https://doi.org/10.1097/00007890-199605270-00014
11. Costa MP, Silva RS, Oliveira CL, Lima MS, Almeida AF, Soares MD, et al. Clinical, laboratorial and evolutionary aspects of pediatric patients with liver disease due to alpha-1 antitrypsin deficiency. Arq Gastroenterol, 2023; 60(4): 438-49. https://doi.org/10.1590/S0004-2803.230402023-71
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Stella Maria Macêdo, Elodie Bomfim Hyppolito, Karen Suzyanne Coelho Gomes, Larissa Ponte Dias, Larissa Peixoto Teixeira, Ana Leatrice de Oliveira Sampaio, Denissa Ferreira Gomes de Mesquita, Clébia Azevedo de Lima, Bartolomeu Feitosa Neto, Antônio Brazil Viana Júnior, Gustavo Rêgo Coelho, José Huygens Parente Garcia

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.






